BioSpace News Archive

Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022

Pharnext SA announces that findings on symptoms burden of Charcot-Marie-Tooth Disease Type 1A from the ‘Real-World’ Digital Lifestyle Study, CMT&Me, will be presented in three poster presentations at the upcoming International Congress on Neuromuscular Disease 2022.

June 28, 2022
·
3 min read
Biotech Beach

Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

Illumina, Inc. announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health.

June 28, 2022
·
6 min read
Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody® Drug Discovery and Development Technology in Rare Diseases

Confo Therapeutics announced that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship.

June 28, 2022
·
3 min read
Biotech Bay

IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a potential first-in-class Pol Theta Helicase development candidate.

June 28, 2022
·
5 min read
Biotech Bay

French Defense Innovation Agency Investigates the Use of DNA Script’s SYNTAX System to Synthesize Custom qPCR Probes for On-demand Detection of Biothreats

DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System DNA printer.

June 28, 2022
·
3 min read
Bio NC

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

Roivant Sciences and Pfizer announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality.

June 28, 2022
·
11 min read
Policy

Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

Kite, a Gilead Company, announces that the European Commission has approved its CAR T-cell therapy Yescarta® for the treatment of adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

June 28, 2022
·
18 min read
Business

Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

Roivant Sciences Ltd. reported its financial results for the fourth quarter and fiscal year ended March 31, 2022 and provided an update on the Company’s operations.

June 28, 2022
·
22 min read
Drug Development

Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

Ascletis Pharma Inc. announces that the first subject has been dosed in the China Phase II clinical trial of ASC22 in combination with anti-retroviral therapy for immune restoration/ functional cure of human immunodeficiency virus 1 infection.

June 28, 2022
·
4 min read
Drug Development

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

Pyxis Oncology, Inc., an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, announced that the Company will present at the H.C. Wainwright Preclinical Cancer Drug Discovery - Antibody Drug Conjugates virtual conference.

June 28, 2022
·
1 min read